Multidisciplinary Reviews

REVIEW ARTICLE
Published Online: March 13, 2024
https://doi.org/10.31893/multirev.2024094

Role of magnesium sulfate in pregnancy: A comprehensive review of benefits and risks

Mayur Wanjari[a] ✉ | Sampada Late[b] | Seema Umate[c] | Minakshi Choudhary[c] | Pratiksha Munjewar[d] | Tejaswee Lohakare[e] | Ranjana Sharma[f] | Seema Singh[d] | Jaya Gawai[g] | Vaishali Taksande[h] | Deeplata Mendhe[i] | Abhyuday Meghe[j]

[a]Department of Research and Development, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Sawangi, Wardha, Maharashtra, India.
[b]Nursing officer, Government Hospital, Samudrapur, Wardha, Maharashtra, India.
[c]Department of Nursing, Shalinitai Meghe College of Nursing, Datta Meghe Institute of Medical Sciences, Sawangi, Wardha, Maharashtra, India.
[d]Department of Medical Surgical Nursing, Smt. Radhikabai Meghe Memorial College of Nursing, Datta Meghe Institute of Medical Sciences, Sawangi, Wardha, Maharashtra, India.
[e]Department of Child Health Nursing, Smt. Radhikabai Meghe Memorial College of Nursing, Datta Meghe Institute of Medical Sciences, Sawangi, Wardha, Maharashtra, India.
[f]Department of Medical Surgical Nursing, Shalinitai Meghe College of Nursing, Datta Meghe Institute of Medical Sciences, Sawangi, Wardha, Maharashtra, India.
[g]Department of Mental Health Nursing, Smt. Radhikabai Meghe Memorial College of Nursing, Datta Meghe Institute of Medical Sciences, Sawangi, Wardha, Maharashtra, India.
[h]Department of Obstetrics and Gynecology Nursing, Smt. Radhikabai Meghe Memorial College of Nursing, Datta Meghe Institute of Medical Sciences, Sawangi, Wardha, Maharashtra, India.
[i]Department of Community Health Nursing, Smt. Radhikabai Meghe Memorial College of Nursing, Datta Meghe Institute of Medical Sciences, Sawangi, Wardha, Maharashtra, India.
[j]Chief Executive Officer of Acharya Vinoba Bhave Rural Hospital, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Sawangi, Wardha, Maharashtra, India.

Abstract Magnesium sulfate is a versatile therapeutic agent in maternal-fetal medicine, and its use during pregnancy has led to various clinical scenarios. This comprehensive review examines the multifaceted role of magnesium sulfate, addressing its benefits and potential risks. The mineral compound is limited for its efficacy in preventing and managing preeclampsia and eclampsia, providing neuroprotection for preterm infants, delaying preterm labor, and offering potential advantages in maternal and fetal health. However, its administration is complex, encompassing a range of maternal and fetal side effects and long-term implications. The decision to utilize magnesium sulfate during pregnancy necessitates a balanced assessment of its advantages and disadvantages, underscored by patient-centered care and shared decision-making. Future research and practice guidelines include pursuing personalized medicine, optimal dosing and administration, long-term follow-up, global health initiatives, and ethical considerations. The evolving landscape of research and emerging insights will continue to enhance maternal care and contribute to improved health outcomes for pregnant women and their infants.

Keywords: magnesium sulfate, pregnancy, obstetric complications, neuroprotection, tocolytic agents, maternal-fetal medicine

1. Introduction

Magnesium sulfate, a simple chemical compound composed of magnesium and sulfur, has long been utilized in obstetrics and gynecology for its various therapeutic applications during pregnancy. When administered under proper medical supervision, this mineral compound plays a crucial role in managing several obstetric conditions, making it an essential tool in the toolkit of maternal-fetal medicine (Barbosa et al. 2010). Historically, magnesium sulfate has gained prominence as a critical intervention in the prevention and treatment of preeclampsia and eclampsia, life-threatening hypertensive disorders that can affect pregnant women. Its efficacy in preventing seizures associated with eclampsia has led to its widespread adoption as a standard of care in high-risk pregnancies, potentially saving the lives of both mothers and their unborn children (Padda et al., n.d.).

While the beneficial effects of magnesium sulfate during pregnancy are well recognized, it is equally important to acknowledge the potential risks and adverse effects associated with its use. The use of this compound during pregnancy is not without complexities, and healthcare providers must carefully weigh its advantages against possible complications. Understanding the full spectrum of benefits and risks is essential for making informed, evidence-based decisions in clinical practice (Bain et al., 2013). Pregnancy is a delicate and dynamic state, and what benefits one aspect of maternal and fetal health might present risks in another. As such, a comprehensive review of magnesium sulfate during pregnancy should provide a balanced perspective, shedding light on its therapeutic potential and associated challenges (Deeksha et al., 2023).

The primary purpose of this review was to explore the role of magnesium sulfate in pregnancy comprehensively. This entails a detailed examination of the benefits and risks of this approach, both for the expectant mother and the developing

fetus, to equip healthcare professionals with the knowledge necessary for informed decision-making. This review will guide readers through the multifaceted aspects of the use of magnesium sulfate during pregnancy. We will start by delving into its pharmacological properties and mechanisms of action and then by an in-depth exploration of its benefits and a thorough examination of the potential risks and adverse effects associated with its administration. We will also evaluate existing clinical guidelines and practices and offer a comparative analysis of alternative interventions and treatments.

2. Materials and Methods

2.1. Magnetic Sulfate: Pharmacological Properties and Mechanisms of Action

2.1.1. Chemical composition and properties of magnesium sulfate

Magnesium sulfate, often represented as MgSO4, is a chemical compound composed of magnesium (Mg), sulfur (S), and oxygen (O). It is available in various forms, including anhydrous and hydrated forms. The most common hydrated form used in medical applications is magnesium sulfate heptahydrate, which contains seven water molecules for each magnesium and sulfate ion. This hydrated state is vital because it affects the compound's solubility and release kinetics in the body (PubChem n.d.). Magnesium sulfate is a white, crystalline substance that dissolves readily in water at neutral pH. This characteristic makes it suitable for intravenous and intramuscular administration, ensuring rapid and controlled delivery when required (“Magnesium Sulphate Mgso4: Topics by Science.Gov” n.d.).

2.1.2. Physiological role of magnesium sulfate in the body

Magnesium is an essential mineral in the human body that participates in numerous physiological processes. It is involved in enzymatic reactions, muscle contraction, nerve function, and blood pressure regulation. During pregnancy, the demand for magnesium increases to support the growth and development of the fetus, as well as maternal adaptations to pregnancy (Khayat, Fanaei, and Ghanbarzehi 2017). Magnesium sulfate supplementation can help maintain the body's magnesium levels within the necessary range during pregnancy, preventing deficiencies that could adversely affect both the mother and the developing fetus. This mineral plays a vital role in neuromuscular function and may contribute to the prevention of seizures in patients with conditions such as eclampsia (Fanni et al., 2021).

2.1.3. Mechanisms of action in the context of pregnancy

1. Vasodilation: The vasodilatory effects of magnesium sulfate are paramount in managing preeclampsia, a hypertensive disorder characterized by elevated blood pressure and vascular constriction. This property allows magnesium sulfate to relax blood vessels, reducing vascular resistance. Consequently, it enhances blood flow to the placenta, which is pivotal for maternal and fetal health. Improved placental perfusion aids in supplying essential nutrients and oxygen to the developing fetus while mitigating the risk of placental insufficiency, which can compromise fetal growth and well-being. This vasodilatory action is an indispensable component of magnesium sulfate in averting the potentially life-threatening complications of preeclampsia (Tang et al., 2018).

2. Neuromuscular Stabilization: The neuromuscular blocking effect of magnesium sulfate is critical for preventing and managing seizures, particularly in patients with eclampsia. In eclampsia, seizures can pose a severe threat to the health and safety of the pregnant woman and her unborn child. Magnesium sulfate functions by stabilizing neuronal cell membranes, thereby diminishing excessive nerve cell activity and inhibiting the initiation of convulsions. This neuromuscular stabilization action acts as a protective shield against the potentially fatal effects of eclampsia, ensuring that expectant mothers are shielded from the neurological complications of this condition (Euser and Cipolla, 2009).

3. Tocolytic Effects: Magnesium sulfate is a tocolytic agent used for managing preterm labor and suppressing uterine contractions. Its capacity to reduce both the frequency and strength of these contractions is a central aspect of its tocolytic action. This slowdown in uterine activity can be pivotal in the clinical setting, as it allows healthcare providers to delay labor intentionally. This delay in labor is particularly advantageous when the fetus is preterm at the gestational age. This approach provides a window of opportunity for the administration of corticosteroids, a medical intervention that is pivotal in promoting the maturation of fetal lungs. The effects of magnesium sulfate as a tool play a vital role in the comprehensive management of preterm labor, ensuring the best possible outcomes for preterm infants (Kawagoe et al., 2011).

4. Neuroprotection: The potential neuroprotective effects of magnesium sulfate, particularly in preterm infants, represent an area of growing interest and significance. This attribute is underscored by its ability to reduce the risk of cerebral palsy and other neurodevelopmental disorders in these vulnerable neonates. Although the precise mechanisms underpinning this neuroprotection have not yet been fully elucidated, research endeavors are actively exploring how magnesium sulfate can shield preterm infants' immature and delicate brains from injury and impairment. This ongoing investigation holds immense promise for potentially safeguarding the neurological health and future well-being of preterm infants, marking a significant advancement in maternal-fetal medicine (Chollat et al., 2018).

2.2. Benefits of Magnesium Sulfate in Pregnancy

2.2.1. Prevention and management of preeclampsia and eclampsia

1. Prevention of Seizures: Magnesium sulfate serves as a pivotal anticonvulsant in the management of eclampsia, a hypertensive disorder that can culminate in life-threatening seizures. The efficacy of magnesium sulfate in preventing and treating seizures is well documented, suggesting that magnesium sulfate is a first-line treatment in such cases. This effect is achieved through the remarkable ability of the mineral to stabilize neuronal cell membranes, a critical mechanism preventing excessive nerve cell activity. By reducing excitability in the nervous system, magnesium sulfate safeguards against the development of convulsions, which, if left uncontrolled, can have dire consequences for both the pregnant woman and her unborn child. Its anticonvulsant action represents a cornerstone of care in eclampsia, ensuring the safety and well-being of expectant mothers and their infants (Padda et al., n.d.).

2. Blood Pressure Control: The vasodilatory properties of magnesium sulfate play an indispensable role in managing preeclampsia, a condition characterized by elevated blood pressure and vascular constriction. By acting as a vasodilator, magnesium sulfate contributes to the control of blood pressure, diminishing the severity of hypertension, which is a hallmark feature of preeclampsia. This vasodilation potently improves placental perfusion, a pivotal factor for maternal and fetal health. Enhanced blood flow to the placenta supports the delivery of essential oxygen and nutrients to the developing fetus, mitigating the risk of placental insufficiency. The improved placental perfusion facilitated by magnesium sulfate underscores its capacity to optimize the well-being of the expectant mother and her unborn child, ultimately contributing to a safer and healthier pregnancy (Chawla et al., 2023).

2.2.2. Neuroprotection for preterm infants

1. Reduction in Cerebral Palsy Risk: Recent studies have explored the potential of antenatal administration of magnesium sulfate to reduce the risk of cerebral palsy in preterm infants. While the precise mechanisms of this neuroprotection remain a subject of ongoing investigation, there is growing evidence to suggest a link between magnesium sulfate and its ability to mitigate brain injury and inflammation. Interfering before birth may help shield the immature and vulnerable brains of preterm infants from the structural and functional abnormalities that can result in cerebral palsy. This neuroprotective effect marks a significant advancement in the field of maternal-fetal medicine, offering hope for improved long-term outcomes and quality of life for preterm infants at risk of this devastating condition (Conde-Agudelo and Romero, 2009).

2. Improved Neonatal Outcomes: Beyond its potential to reduce the risk of cerebral palsy, magnesium sulfate has shown promise in enhancing various other neonatal outcomes. Studies have indicated that its administration may lead to a reduction in the incidence of severe intraventricular hemorrhage, a significant neurological complication in preterm infants. Additionally, the need for mechanical ventilation, which can be associated with various complications, may decrease in neonates exposed to magnesium sulfate. These improvements in neonatal outcomes underscore the multifaceted benefits of magnesium sulfate, extending its positive impact beyond neuroprotection. By mitigating the risk of intraventricular hemorrhage and reducing the reliance on mechanical ventilation, magnesium sulfate contributes to improved overall health and well-being in the delicate population of preterm infants, marking a significant advancement in neonatal care (Conde-Agudelo and Romero, 2009).

2.2.3. Management of preterm labor and prevention of cerebral palsy

1. Tocolytic effects: One of the critical applications of magnesium sulfate in obstetric care is as a tocolytic agent. Magnesium sulfate suppresses uterine contractions in preterm labor, where contractions occur before the desired gestational age. Moreover, these drugs play a crucial role in delaying premature delivery by effectively inhibiting these contractions, providing a valuable window for additional interventions. This delay is particularly valuable in regard to promoting fetal lung maturation. The administration of corticosteroids to expectant mothers to accelerate fetal lung development becomes more effective in a controlled environment, facilitated by the tocolytic effects of magnesium sulfate. This multifaceted approach ensures that the infant's lungs are better prepared for independent breathing, reducing the risk of respiratory distress syndrome and other complications associated with preterm birth (Mayer and Apodaca-Ramos, 2023).

2. Cerebral Palsy Prevention: The tocolytic use of magnesium sulfate in the context of preterm labor has the potential to contribute to the prevention of cerebral palsy in preterm infants. As previously discussed, studies and clinical evidence indicate that antenatal administration of magnesium sulfate may reduce the risk of cerebral palsy in this vulnerable neonatal population. The specific mechanisms underlying this protective effect are still under investigation, but its promise for improving the long-term neurodevelopmental outcomes of preterm infants is significant. The judicious use of magnesium sulfate as a tocolytic agent in preterm labor underscores the multifaceted benefits it offers, extending beyond the immediate goal of delaying delivery to the prevention of severe neurological disorders in preterm infants. This dual impact on maternal and neonatal health underscores its pivotal role in obstetric practice (Rouse et al., 2008).

2.2.4. Other potential benefits for maternal and fetal health

1. Reduction in Postpartum Hemorrhage: The potential role of magnesium sulfate in reducing the risk of postpartum hemorrhage is an area of active investigation. Postpartum hemorrhage is a significant concern in obstetric care, and early studies have suggested that magnesium sulfate may have a hemostatic effect, helping to control excessive bleeding after childbirth. However, additional research is needed to establish its efficacy in this context and to delineate the precise mechanisms through which magnesium sulfate may exert its effects. If proven effective, this approach could provide a valuable addition to the armamentarium of interventions aimed at safeguarding postpartum women's health (Miller et al., 2021).

2. Maternal Seizure Prophylaxis: In high-risk situations, magnesium sulfate is administered prophylactically to prevent seizures in pregnant women, particularly those with a history of eclampsia or other risk factors. This preventive use of magnesium sulfate is crucial for women at elevated risk of seizures, as it acts as a protective shield against the potentially life-threatening complications associated with eclampsia. By stabilizing neuronal cell membranes and reducing excitability in the nervous system, magnesium sulfate is a robust anticonvulsant that ensures the safety of expectant mothers during and after childbirth. Its use in maternal seizure prophylaxis is a testament to its life-saving potential in obstetric emergencies (Cipolla and Kraig, 2011).

3. Antioxidant Properties: The antioxidant properties of magnesium sulfate are of increasing interest in maternal-fetal medicine. During pregnancy, oxidative stress can be a significant concern, particularly in cases of complications. The capacity of magnesium sulfate to act as an antioxidant may protect maternal and fetal tissues against the damaging effects of free radicals. Although the specific mechanisms and clinical applications of this antioxidant are still under exploration, the findings underscore the multifaceted nature of the benefits of magnesium sulfate in pregnancy, extending beyond its more established roles (Sebastiani et al., 2022).

4. Cardioprotective Effects: Research into the potential cardioprotective effects of magnesium supplementation during pregnancy is a subject of ongoing investigation. Cardiovascular complications can pose significant risks to pregnant women, and some studies suggest that magnesium supplementation may have a role in reducing these risks. The exact mechanisms through which magnesium exerts its cardioprotective effects are still under scrutiny, but its promise in mitigating cardiovascular complications represents a significant advancement in maternal care. This potential use of magnesium in cardiovascular health during pregnancy reflects the evolving landscape of its applications beyond traditional obstetric interventions (Zarean and Tarjan, 2017).

2.3. Risks and Adverse Effects of Magnesium Sulfate during Pregnancy

2.3.1. Maternal side effects and complications

1. Flushing and Warmth: A notable side effect reported by many women during magnesium sulfate administration is a sensation of warmth or flushing. This warmth can be pervasive and extend throughout the body, sometimes causing discomfort. Although not typically harmful, this can be a challenging experience for expectant mothers, and healthcare providers should be prepared to address this common side effect with supportive measures such as adjusting the infusion rate or providing reassurance (Popkin et al., 2010).

2. Nausea and vomiting: Nausea and vomiting are frequent side effects of magnesium sulfate, and for some women, these symptoms can be severe enough to necessitate the administration of antiemetic medications. Moreover, nausea and vomiting can be distressing for pregnant women, and healthcare providers need to monitor these symptoms closely to ensure the well-being of the patient and manage these side effects effectively (Einarson et al., 2007).

3. Respiratory Depression: Although rare, high doses of magnesium sulfate can lead to respiratory depression in mothers. Respiratory depression is a potentially severe side effect characterized by a decrease in respiratory rate and depth, which can compromise oxygen exchange. Continuous monitoring of respiratory function is crucial during magnesium sulfate administration to promptly identify signs of respiratory depression and intervene to prevent this severe complication (DE JESUS et al., 2015).

4. Hypotension: The vasodilatory effect of magnesium sulfate can occasionally result in low blood pressure, a condition known as hypotension. This side effect may require intervention to maintain adequate perfusion and prevent any potential adverse consequences of low blood pressure, such as dizziness, fainting, or inadequate oxygen delivery to vital organs (Juibari et al., 2016).

5. Muscle weakness: The neuromuscular effects of magnesium sulfate can lead to muscle weakness or a sensation of heaviness in the limbs. While not harmful, this side effect can be bothersome for some women, mainly affecting their mobility and comfort. Healthcare providers should be attentive to these symptoms and provide the necessary support to manage any discomfort experienced by the patient (“Muscle Weakness: 12 Causes and More” 2019).

6. Renal Dysfunction: In some cases, magnesium sulfate can affect renal function, potentially leading to reduced urine output or elevated serum creatinine levels. Monitoring renal function is a critical aspect of magnesium sulfate administration.

Close observation ensures that any emerging renal dysfunction is detected promptly, allowing timely intervention and treatment adjustment to safeguard the patient's kidney health. This side effect highlights the importance of comprehensive monitoring during magnesium sulfate therapy to ensure maternal safety and well-being (Cunningham et al., 2012).

2.3.2. Fetal and neonatal complications

1. Fetal Depression: One of the primary concerns associated with magnesium sulfate administration during pregnancy is its potential to cross the placental barrier, leading to fetal exposure. While most fetuses tolerate this exposure well, there is a risk of fetal respiratory depression or bradycardia in some cases. These complications can arise as a result of fetal neuromuscular blockade caused by magnesium sulfate. Fetal respiratory depression can impede a newborn's ability to breathe independently immediately after birth, necessitating neonatal resuscitation. Similarly, bradycardia, characterized by a slow heart rate, can pose significant challenges to newborn well-being. Healthcare providers should remain vigilant during magnesium sulfate administration, closely monitoring fetal well-being through techniques such as electronic fetal monitoring to detect and address any concerning fetal responses promptly (Fanni et al., 2021).

2. Hypomagnesemia: Prolonged maternal administration of magnesium sulfate can lead to neonatal hypomagnesemia, a condition characterized by abnormally low magnesium levels in the newborn's blood. This can occur when the infant's magnesium stores become depleted due to continued exposure to high levels of magnesium sulfate in utero. Neonatal hypomagnesemia can manifest with symptoms such as muscle weakness and other complications, potentially impacting the ability of the newborn to thrive and develop normally. Healthcare providers should be aware of the risk of neonatal hypomagnesemia and take measures to monitor and manage the condition if it arises (Gragossian et al., 2023).

3. Intraventricular Hemorrhage: Several studies have suggested a potential association between the use of magnesium sulfate during pregnancy and an increased risk of intraventricular hemorrhage in preterm infants. Intraventricular hemorrhage is a significant neurological complication that can lead to various adverse outcomes, including cerebral palsy and developmental delays. However, further research is needed to establish a causal relationship between magnesium sulfate use and intraventricular hemorrhage. The potential association underscores the need for careful consideration when using magnesium sulfate in preterm labor and the importance of ongoing research to better understand the related risks and benefits (Moradi et al., 2020).

4. Skeletal Demineralization: In scenarios of long-term exposure to magnesium sulfate, there is a concern that magnesium sulfate may contribute to neonatal skeletal demineralization. Skeletal demineralization refers to the loss of minerals from bones, potentially affecting newborn bone health in the long term. This is an area of concern, particularly in prolonged maternal magnesium sulfate therapy cases. Healthcare providers should be cautious when considering extended use and closely monitoring neonates for any signs of skeletal demineralization or associated complications. The potential impact on bone health underscores the need for a balanced evaluation of the risks and benefits of magnesium sulfate use in pregnancy (Wedig et al., 2006).

2.3.3. Long-term implications and concerns

1. Neurodevelopmental Outcomes: Although magnesium sulfate has shown promise in reducing the risk of cerebral palsy in preterm infants, the long-term neurodevelopmental outcomes of infants exposed to this drug in utero remain a subject of ongoing study and discussion. While reducing cerebral palsy risk is a significant advancement, researchers are keen to comprehensively assess the broader impact of magnesium sulfate on cognitive, motor, and sensory development, as well as potential side effects or complications associated with magnesium sulfate exposure. This includes investigating potential cognitive or behavioral outcomes, developmental delays, and whether other neurological concerns may offset the protective effect on cerebral palsy risk. A deeper understanding of these long-term neurodevelopmental outcomes is vital for optimizing the use of magnesium sulfate and providing comprehensive care to both mothers and infants (Bozkurt et al., 2016).

2. Renal Function: The potential long-term impact of magnesium sulfate on renal function in mothers and infants exposed to the drug during pregnancy is a subject of ongoing research. While magnesium sulfate has well-documented effects on renal function during its administration, it is crucial to determine whether these effects have lasting consequences. Monitoring renal function in the postpartum period and beyond is essential for assessing potential changes in and understanding the ramifications for maternal and neonatal health. Any alterations in renal function must be carefully evaluated, as they could have implications for long-term well-being (Olofsson et al., 1992).

3. Skeletal Health: The effects of neonatal exposure to magnesium sulfate on long-term bone health are an area of interest in the medical community. Skeletal demineralization, reported in some cases of prolonged maternal magnesium sulfate therapy, raises concerns about the potential impact on neonatal bone health and development. Researchers are investigating whether these effects persist over time and whether they result in any bone-related complications for the newborn. A better understanding of the influence of magnesium sulfate on skeletal health is critical for assessing the safety and efficacy of a drug in maternal-fetal medicine (Matsuda et al., 1997).

4. Optimal Dosing and Duration: Determining the optimal dosage and duration of magnesium sulfate administration for various obstetric conditions is a continuing challenge. The choice of dosage and duration can significantly influence both the benefits and risks associated with magnesium sulfate use. Achieving a delicate balance between obtaining therapeutic advantages and minimizing potential side effects remains a central concern. Researchers are continuously refining dosing regimens and administration protocols to ensure that magnesium sulfate maximizes its benefits while minimizing any potential harm. Achieving this balance is critical in providing effective, safe, and individualized care to pregnant women and their infants (Shennan et al., 2021).

2.4. Clinical Guidelines and Current Practices for the Use of Magnesium Sulfate in Pregnancy

2.4.1. Review of existing guidelines from reputable medical organizations

1. The American College of Obstetricians and Gynecologists (ACOG): The American College of Obstetricians and Gynecologists (ACOG) plays a pivotal role in maternal-fetal medicine by offering comprehensive guidelines for using magnesium sulfate to prevent and treat preeclampsia and eclampsia. These guidelines are trusted resources for healthcare providers, offering detailed recommendations on various aspects of magnesium sulfate administration, including dosing regimens, routes of administration, and essential monitoring of maternal and fetal well-being. The ACOG's guidelines are instrumental in ensuring that healthcare professionals have a clear and evidence-based framework for using magnesium sulfate, enhancing the quality of care for pregnant women (Bell, 2010).

2. The World Health Organization (WHO): The WHO takes on a global perspective by providing guidance on the use of magnesium sulfate to manage preeclampsia and eclampsia, with a particular focus on resource-limited settings. These guidelines are paramount in regions where access to healthcare resources and expertise may be limited. The WHO's recommendations serve as a lifeline, ensuring that magnesium sulfate is administered to save lives and improve maternal and fetal outcomes. By emphasizing safe and effective use, the WHO's guidance contributes to reducing the burden of preeclampsia-related complications on a global scale (“WHO Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia” n.d.).

3. The Royal College of Obstetricians and Gynecologists (RCOG): RCOG provides specific guidelines on the use of magnesium sulfate in the United Kingdom, aligning with best practices and evidence-based approaches for preeclampsia and eclampsia. These guidelines offer valuable insights into the dosing, administration, and monitoring of magnesium sulfate in the UK context, ensuring that the benefits of this intervention are realized while minimizing potential risks. The RCOG's guidance is integral to obstetrics and gynecology practices in the UK, as it supports healthcare providers in delivering high-quality maternal care (“Severe Pre-Eclampsia/Eclampsia, Management (Green-Top Guideline No. 10A)” n.d.).

4. The American Academy of Pediatrics (AAP): The AAP addresses the use of magnesium sulfate for neuroprotection in preterm infants. These guidelines are essential for neonatologists, pediatricians, and other healthcare professionals involved in caring for preterm neonates at risk of cerebral palsy. The AAP's guidance focuses on the administration and dosing of magnesium sulfate to reduce the risk of cerebral palsy in this vulnerable population. By providing a clear framework for using magnesium sulfate in neonatal care, the AAP's recommendations contribute to improved long-term outcomes in preterm infants and reinforce the importance of neuroprotection in pediatrics (Chollat et al., 2018).

2.4.2. Variations in practice across different healthcare settings

1. Resource availability: Access to essential medications such as magnesium sulfate can be challenging in resource-limited settings. Healthcare facilities may face procurement, storage, and distribution constraints, which can significantly impact the utilization of magnesium sulfate for preventing and treating preeclampsia and eclampsia. Limited financial resources, inadequate infrastructure, and supply chain difficulties may result in irregular or insufficient access to these critical medications. Overcoming these resource-related barriers is crucial for ensuring that magnesium sulfate reaches those individuals who need it most, improving maternal and fetal outcomes in resource-limited environments (Katageri et al., 2018).

2. Local Protocols: Several healthcare institutions may develop clinical protocols based on regional preferences, clinical expertise, or historical practices. These locally established protocols can differ from established national or international guidelines. As a result, the use of magnesium sulfate may vary, even within a single region or country. While these local protocols may be tailored to meet specific needs, they can introduce variability in the administration of magnesium sulfate and may only sometimes align with evidence-based best practices. Ensuring that local protocols are in harmony with established guidelines is essential for maintaining consistency and quality of care (Aaserud et al., 2005).

3. Clinical Judgment: Healthcare providers must often exercise clinical judgment when patient needs or circumstances deviate from established guidelines. Such deviations can occur when a patient presents with unique clinical characteristics, contraindications, or other factors that warrant a personalized approach. Clinical judgment can influence the decision to use magnesium sulfate or adjust its dosing and administration. While clinical judgment is vital to patient-centered care, it should be exercised with the best available evidence to ensure that magnesium sulfate is used optimally and safely (Fogel, 2018).

4. Regulatory and Legal Considerations: Differences in legal and regulatory frameworks can substantially impact the availability and administration of magnesium sulfate in various healthcare settings. Regulatory requirements for drug licensing, prescription, and administration may vary by country or region, leading to differences in accessibility and utilization. Legal considerations, such as liability issues and the extent of healthcare provider autonomy, can also influence the decision-making process regarding the use of magnesium sulfate. Ensuring alignment between clinical practice, regulations, and legal standards is essential for promoting the safe and effective use of these medications (Commissioner, 2021).

2.4.3. Challenges in implementation and adherence to guidelines

1. Awareness and Education: The awareness and education of healthcare providers play a significant role in adherence to guidelines for magnesium sulfate administration. Some healthcare providers may need to be fully informed about the existing guidelines or lack comprehensive training in properly administering magnesium sulfate. This knowledge gap can result in variations in practice and may hinder the optimal utilization of this medication. Ongoing education and training programs are essential to ensure that healthcare professionals are well informed and competent following established guidelines (Bain et al., 2015).

2. Resource Constraints: Adhering to magnesium sulfate guidelines can be challenging in healthcare settings with limited resources. Resource constraints, such as a shortage of healthcare personnel, equipment, and essential medications, can impede the consistent use of magnesium sulfate. The availability of trained healthcare personnel is critical for proper administration, but a lack of necessary equipment and medications can lead to interruptions or deviations from guidelines. Addressing these resource limitations is essential for effectively implementing magnesium sulfate protocols (Long et al., 2017).

3. Patient Preferences and Autonomy: Patient preferences and cultural factors can significantly influence the acceptance and use of magnesium sulfate. Sometimes, patients may decline administration due to concerns, cultural beliefs, or personal preferences. Healthcare providers must respect patient autonomy and engage in open communication to address these concerns, educate patients about the benefits and risks of magnesium sulfate, and make informed decisions collaboratively. Ensuring culturally sensitive care and involving patients in decision-making are vital for guideline adherence (Alfahmi, 2022).

4. Monitoring and Quality Control: Ensuring consistent adherence to magnesium sulfate guidelines and monitoring its administration can be challenging, particularly in large healthcare systems with complex workflows. Proper oversight and quality control mechanisms are necessary to track compliance with guidelines and identify areas for improvement. Monitoring may involve electronic health records, regular audits, and feedback mechanisms to maintain the highest standards of care. Implementing robust monitoring systems is essential for aligning clinical practice with established guidelines (Eddy et al., 2022).

5.Documentation and Reporting: Proper documentation of magnesium sulfate administration and patient outcomes is essential for maintaining the quality of care and for research and quality improvement purposes. However, consistent and accurate documentation can be challenging to maintain. Healthcare providers must diligently record the details of magnesium sulfate administration, patient responses, and any adverse events. Additionally, reporting mechanisms should be used to communicate outcomes and complications effectively, facilitating continuous improvement in guideline adherence and patient safety. Accurate documentation and reporting are essential for maintaining and enhancing the standard of care for pregnant women (Azria et al., 2004).

2.5. Comparative analysis of alternative interventions and treatments

2.5.1. Comparison with other tocolytic agents for preterm labor?

1. β2-Adrenergic Agonists (Terbutaline): β2-agonists, such as terbutaline, are well-established tocolytic agents that delay preterm labor. A comparative analysis should thoroughly assess the efficacy, safety, and side effect profiles of magnesium sulfate. It is critical to evaluate the ability of these compounds to inhibit uterine contractions, their impact on maternal and fetal well-being, and their potential side effects, such as tachycardia or hyperglycemia. Comparisons should consider factors such as the gestational age at which they are most effective and their overall impact on neonatal outcomes to determine the most appropriate tocolytic choice for specific clinical scenarios (Younger et al., 2017).

2. Calcium Channel Blockers (nifedipine): Calcium channel blockers such as nifedipine represent an alternative tocolytic option for managing preterm labor. In addition to magnesium sulfate, a comparative analysis should explore the efficacy of these agents and potential maternal and fetal side effects. This assessment should consider their mechanism of action, the speed of onset, and the extent to which they inhibit contractions. Additionally, evaluating their impact on blood pressure, fetal heart rate, and neonatal outcomes is essential for guiding clinical decision-making. Comparisons can help identify the scenarios in which calcium channel blockers may be the preferred tocolytic agent (Flenady et al., 2014).

3. Prostaglandin synthetase inhibitors (indomethacin): Prostaglandin synthetase inhibitors, such as indomethacin, function by inhibiting the synthesis of prostaglandin, a key component of uterine contractions. Comparative analysis should consider the effectiveness of these inhibitors in managing preterm labor and the potential risks associated with their use. It is essential to assess the impact of these agents on maternal and fetal health, including potential side effects such as gastrointestinal irritation and closure of the ductus arteriosus in the fetus. This evaluation can help healthcare providers make informed decisions about tocolytic therapy in specific clinical situations (Loudon et al., 2003).

4. Atosiban: Atosiban, a selective oxytocin receptor antagonist, offers an intriguing alternative to magnesium sulfate for inhibiting uterine contractions. Comparative analysis should explore its safety and efficacy in the context of preterm labor, with a particular focus on its potential as an alternative to magnesium sulfate. It is crucial to assess its impact on maternal and fetal well-being, the speed of action, and any associated side effects. Comparisons can provide insights into when atosiban may be the preferred tocolytic agent, especially when magnesium sulfate use may be contraindicated or associated with adverse effects. This analysis can guide clinical decision-making and enhance the options for managing preterm labor (López Gómez et al., 2018).

2.5.2. Contrast with alternative neuroprotective strategies for preterm infants

1. Antenatal Corticosteroids: Antenatal corticosteroids, such as betamethasone and dexamethasone, are administered to promote fetal lung maturation in patients with threatened preterm delivery. A comparative assessment should examine the neuroprotective benefits of corticosteroids relative to magnesium sulfate in preterm infants. This evaluation should focus on the ability of corticosteroids to reduce the risk of cerebral palsy and other neurodevelopmental disorders. Considering the mechanisms of action, timing of administration, and potential side effects associated with corticosteroids compared to magnesium sulfate is essential. A comprehensive analysis can help healthcare providers determine the most suitable approach for enhancing neonatal outcomes in the context of preterm birth (Bonanno and Wapner, 2012).

2. Hypothermia Therapy: Hypothermia therapy involves cooling the body temperature of asphyxiated newborns to mitigate brain injury. Comparative analysis should evaluate the effectiveness and safety of hypothermia therapy compared to magnesium sulfate in reducing the risk of cerebral palsy and other neurodevelopmental disorders. This assessment should consider the conditions for which hypothermia therapy is indicated, its mechanisms of action in preventing brain injury, and potential side effects. Comparing hypothermia therapy with magnesium sulfate can provide valuable insights into the choice of neuroprotective strategies for neonates and guide clinical decision-making in cases of perinatal asphyxia (Lee et al., 2019).

3. Umbilical Cord Milking: Umbilical cord milking is a technique that involves manually squeezing or milking the umbilical cord during delivery to increase the transfer of oxygenated blood to the newborn. A comparative analysis should assess its potential neuroprotective effects on preterm infants treated with magnesium sulfate. This evaluation should consider the physiological mechanisms by which umbilical cord milking may benefit neonates, the circumstances in which it is applied, and any potential risks or complications associated with the procedure. Comparing umbilical cord milking with magnesium sulfate can help determine the optimal approach for enhancing neuroprotection in preterm infants and guide clinical practice in various obstetric scenarios (Jain and Mehendale, n.d.).

2.5.3. Assessment of the relative efficacy and safety profiles

1. Efficacy: A comparative analysis should rigorously assess the efficacy of magnesium sulfate in achieving its intended outcomes, whether it prevents seizures in eclampsia patients, delays preterm labor, or reduces the risk of cerebral palsy in preterm infants. The strength of the evidence supporting these outcomes should be considered, as should the clinical scenarios in which magnesium sulfate is most effective and the degree of benefit achieved compared to alternative approaches. Factors such as onset speed and therapeutic effect durability should also be considered (Conde-Agudelo and Romero, 2009).

2. Safety: Safety is a paramount consideration in comparative analysis. The safety profile of magnesium sulfate should be thoroughly examined in terms of maternal and fetal side effects, such as respiratory depression, hypotension, and renal dysfunction. Comparing these safety concerns with those associated with alternative interventions is critical for understanding the risk–benefit ratio. Factors such as the frequency and severity of side effects and their reversibility should be considered to guide the selection of the most suitable intervention (Bain, et al., 2013).

3. Long-Term Outcomes: The analysis investigated the impact of these interventions on long-term maternal and neonatal outcomes, including neurodevelopmental progress and potential complications. For magnesium sulfate and alternative strategies, this involves examining the effects on cognitive, motor, and sensory development in preterm infants and assessing any potential complications or adverse outcomes that may arise over time. Understanding the long-term consequences of these interventions is pivotal for providing comprehensive care and making informed clinical decisions (Zeng et al., 2016).

4. Cost-effectiveness: Cost-effectiveness is essential for comparative analysis because of the financial burden on healthcare systems and families. The evaluation should assess the overall cost of administering magnesium sulfate versus

alternative treatments and weigh this against the benefits and outcomes achieved. This analysis can help healthcare providers and policymakers make informed decisions about resource allocation and the cost-effectiveness of various treatment options (Simon et al., 2006).

5. Individual Patient Factors: Recognizing the role of individual patient factors in the choice between magnesium sulfate and alternatives is crucial. The analysis should consider patient-specific characteristics, such as gestational age, comorbidities, and obstetric conditions. These factors may influence the suitability and safety of different interventions for specific patients. A comparative analysis should help guide the selection of the most appropriate treatment on a case-by-case basis, ensuring that individual patient needs and circumstances are carefully considered (Eddy et al., 2022).

2.6. Clinical Trials and Recent Research Findings

2.6.1. Overview of recent clinical trials and studies on magnesium sulfate

1. Efficacy in Preeclampsia: Recent clinical trials have made significant contributions to understanding the effectiveness of magnesium sulfate in preventing and managing preeclampsia and eclampsia. These studies have explored optimal dosing regimens, routes of administration, and patient selection criteria. By refining these parameters, researchers seek to enhance outcomes while minimizing potential side effects. Ongoing research is crucial for providing evidence-based guidance to healthcare providers and ensuring that magnesium sulfate is used as a cornerstone in the management of hypertensive disorders during pregnancy (Padda et al., n.d.).

2. Tocolytic Use: Clinical trials have investigated the use of magnesium sulfate as a tocolytic agent in preterm labor. Researchers are actively investigating the efficacy of these agents in combination with other tocolytic agents, such as beta-agonists and calcium channel blockers, to determine the most effective treatment for delaying preterm delivery. These trials aim to provide insights into the optimal choice of tocolytic therapy for specific clinical scenarios, considering factors such as gestational age, maternal health, and the risk of neonatal complications. The findings from these trials can significantly influence clinical practice and improve neonatal outcomes in cases of preterm birth (Wilson et al., 2022).

3. Neuroprotection: Recent studies have been dedicated to revealing the neuroprotective effects of magnesium sulfate in preterm infants. These trials are focused on refining dosing strategies and determining the ideal candidates for treatment to reduce the risk of cerebral palsy and other neurodevelopmental disorders. Ongoing research aims to provide a more comprehensive understanding of the mechanisms underlying the neuroprotective effects of magnesium sulfate and to optimize its use in clinical practice. This knowledge is pivotal for enhancing preterm infants' long-term outcomes and quality of life (Chollat et al., 2018).

4. Combination Therapies: Several clinical trials have explored the potential benefits of combining magnesium sulfate with other interventions, such as antenatal corticosteroids or hypothermia therapy, for enhancing neuroprotection and improving long-term outcomes in preterm infants. These studies investigated the synergistic effects of different therapies and their impact on reducing cerebral palsy risk and other complications. The findings from these trials may offer healthcare providers new strategies for optimizing care and providing comprehensive solutions for neonatal neuroprotection in high-risk pregnancies (Chollat et al., 2018).

2.6.2. Novel insights and developments in the field

1. Pharmacokinetics: Ongoing research into the pharmacokinetics of magnesium sulfate during pregnancy has yielded valuable insights into its distribution, metabolism, and elimination. This enhanced understanding informs dosing strategies to optimize efficacy while minimizing side effects. Researchers are uncovering how the drug is processed in pregnant women, allowing for more precise dosing regimens that can adapt to individual patient factors, such as gestational age and renal function. This knowledge enhances the safety and efficacy of magnesium sulfate administration during pregnancy (Lu and Nightingale, 2000).

2. Biomarkers: Biomarker research is a promising area for identifying predictive markers to help determine which pregnant women are most likely to benefit from magnesium sulfate therapy. By tailoring treatment to individual patients based on specific biomarkers, healthcare providers can optimize the use of magnesium sulfate and potentially reduce the risk of adverse effects in nonresponders. This personalized medicine approach is a significant step toward enhancing patient care and minimizing unnecessary exposure to the drug (Petla et al., 2013).

3. Neuroprotection Mechanisms: Studies investigating the neuroprotective mechanisms of magnesium sulfate in preterm infants are shedding light on the specific pathways by which the drug exerts its beneficial effects. These insights could inform future drug development and intervention strategies. Researchers are investigating the specific cellular and molecular processes that underlie the neuroprotective effects of magnesium sulfate, which may lead to targeted therapies to minimize the risk of cerebral palsy and other neurodevelopmental disorders in preterm infants (Galinsky et al., 2020).

4. Long-Term Follow-Up: Longitudinal studies that track the development of infants exposed to magnesium sulfate in utero provide critical data on long-term neurodevelopmental outcomes and overall health. This research is essential for understanding the sustained impact of magnesium sulfate administration and the potential benefits or risks that may

manifest as children grow. The insights gained from long-term follow-up studies contribute to the ongoing evaluation of the safety and efficacy of these drugs, ensuring that they continue to be valuable tools in maternal-fetal medicine (Doll et al., 2014).

2.6.3. Future directions for research and clinical practice

1. Personalized Medicine: Maternal-fetal medicine increasingly embraces personalized medicine, where treatment decisions are customized to suit each patient's unique characteristics and needs. Future research will likely focus on identifying specific biomarkers, genetic factors, and clinical indicators to guide the personalized use of magnesium sulfate and other interventions. This individualized approach aims to maximize the effectiveness of treatment while minimizing the risk of adverse effects, taking into account patient-specific factors such as gestational age, comorbidities, and genetic predispositions (Stevenson et al., 2021).

2. Optimizing Dosing and Administration: Research will continue to refine dosing regimens and administration routes for magnesium sulfate. The goal is to strike the right balance between therapeutic benefits and minimizing side effects. This may involve further investigations into dosage adjustments based on patient characteristics, improved drug delivery methods, and more precise timing of administration. The optimization of dosing and administration is essential for ensuring that magnesium sulfate remains a safe and effective intervention during pregnancy (Gordon et al., 2014).

3. Integration of New Technologies: Advances in medical technology, including telemedicine and remote monitoring, are likely to play a role in administering and managing magnesium sulfate during pregnancy. These technologies can be useful in remote or underserved areas where access to specialized care may be limited. Remote monitoring and telemedicine can help healthcare providers deliver timely and appropriate care, monitor treatment responses, and address potential complications, ultimately improving patient outcomes (Kusyanti et al., 2022).

4. Global Health Initiatives: Efforts to improve access to magnesium sulfate in resource-limited settings will remain a priority. Magnesium sulfate is a crucial intervention for reducing maternal and neonatal mortality associated with preeclampsia and preterm birth. Future research and initiatives will focus on strategies to ensure that this life-saving medication is readily available and effectively administered in regions with scarce healthcare resources. This includes supply chain management, education and training programs, and community-based interventions to raise awareness and improve access (von Dadelszen and Magee, 2016).

5. Ethical considerations: Future research will also explore ethical considerations surrounding the use of magnesium sulfate. This is particularly relevant in cases where patient autonomy, informed consent, and cultural factors intersect with clinical guidelines. Ethical inquiries strike a balance between respecting the preferences and values of individual patients while upholding evidence-based clinical practices. Exploring these ethical dimensions is essential for ensuring that magnesium sulfate administration aligns with medical guidelines and the ethical principles of patient-centered care (Rao, 2008).

3. Final Considerations

In conclusion, magnesium sulfate is vital in obstetric care and has a range of benefits while also presenting potential risks that require careful consideration. It plays a crucial role in preventing and managing conditions such as preeclampsia and eclampsia, providing neuroprotection for preterm infants and facilitating tocolytic efforts to delay preterm labor. However, its administration is not without maternal and neonatal side effects and long-term implications. The decision to use magnesium sulfate during pregnancy should be guided by a balanced assessment of its advantages and disadvantages, considering individual patient factors and preferences. This comprehensive review underscores the importance of patient-centered care, where the choice to use magnesium sulfate is based on a thorough understanding of its benefits and risks, clear communication with expectant mothers, and shared decision-making. The field of maternal-fetal medicine should continue to evolve by focusing on research to optimize dosing and administration, personalize treatment using biomarkers, and ensure long-term follow-up of infants exposed to magnesium sulfate. Efforts to improve access to this essential intervention, especially in resource-limited settings, remain crucial, as do efforts to address ethical dilemmas in the context of patient autonomy. Integrating emerging insights will enhance maternal care and improve health outcomes for pregnant women and their infants.

Ethical considerations

Not applicable

Conflict of interest

The authors declare no conflicts of interest.

Funding

This research did not receive any financial support.

References

Aaserud, M., Lewin, S., Innvaer, S., Paulsen, E. J., Dahlgren, A. T., Trommald, M., Duley, L., Zwarenstein, M., & Oxman, A. D. (2005). Translating research into policy and practice in developing countries: A case study of magnesium sulphate for pre-eclampsia. BMC Health Services Research, 5, 68. https://doi.org/10.1186/1472-6963-5-68

Alfahmi, M. Z. (2022). Patients' preference approach to overcome the moral implications of family-centred decisions in Saudi medical settings. BMC Medical Ethics, 23(December), 128. https://doi.org/10.1186/s12910-022-00868-8

Azria, E., Tsatsaris, V., Goffinet, F., Kayem, G., Mignon, A., & Cabrol, D. (2004). Magnesium sulfate in obstetrics: current data. Journal De Gynecologie Obstetrique Et Biologie De La Reproduction, 33(6 Pt 1), 510-517. https://doi.org/10.1016/s0368-2315(04)96564-7

Bain, E., Bubner, T., Ashwood, P., Van Ryswyk, E., Simmonds, L., Reid, S., Middleton, P., & Crowther, C. A. (2015). Barriers and enablers to implementing antenatal magnesium sulphate for fetal neuroprotection guidelines: A study using the theoretical domains framework. BMC Pregnancy and Childbirth, 15(1), 176. https://doi.org/10.1186/s12884-015-0618-9

Bain, E. S., Middleton, P. F., & Crowther, C. A. (2013). Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: A systematic review. BMC Pregnancy and Childbirth, 13(October), 195. https://doi.org/10.1186/1471-2393-13-195

Barbosa, F. T., Barbosa, L. T., Jucá, M. J., & Cunha, R. M. (2010). Applications of magnesium sulfate in obstetrics and anesthesia. Revista Brasileira De Anestesiologia, 60(1), 104-110. https://doi.org/10.1016/s0034-7094(10)70013-1

Bell, M. J. (2010). A historical overview of preeclampsia-eclampsia. Journal of Obstetric Gynecologic and Neonatal Nursing, 39(5), 510-518. https://doi.org/10.1111/j.1552-6909.2010.01172.x

Bonanno, C., & Wapner, R. J. (2012). Antenatal corticosteroids in the management of preterm birth: Are we back where we started? Obstetrics and Gynecology Clinics of North America, 39(1), 47-63. https://doi.org/10.1016/j.ogc.2011.12.006

Bozkurt, O., Eras, Z., Canpolat, F. E., Oguz, S. S., Uras, N., & Dilmen, U. (2016). Antenatal magnesium sulfate and neurodevelopmental outcome of preterm infants born to preeclamptic mothers. The Journal of Maternal-Fetal & Neonatal Medicine, 29(7), 1101-1104. https://doi.org/10.3109/14767058.2015.1035641

Chawla, N., Shah, H., Huynh, K., Braun, A., Wollocko, H., & Shah, N. C. (2023). The role of platelet-activating factor and magnesium in obstetrics and gynecology: Is there crosstalk between pre-eclampsia, clinical hypertension, and HELLP syndrome? Biomedicines, 11(5), 1343. https://doi.org/10.3390/biomedicines11051343

Chollat, C., Sentilhes, L., & Marret, S. (2018). Fetal neuroprotection by magnesium sulfate: From translational research to clinical application. Frontiers in Neurology, 9(April), 247. https://doi.org/10.3389/fneur.2018.00247

Cipolla, M. J., & Kraig, R. P. (2011). Seizures in women with preeclampsia: Mechanisms and management. Fetal and Maternal Medicine Review, 22(02), 91-108. https://doi.org/10.1017/S0965539511000040

Commissioner, Office of the. (2021). Classification of products as drugs and devices and additional product classification issues. FDA. Retrieved May 12, 2021, from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/classification-products-drugs-and-devices-and-additional-product-classification-issues

Conde-Agudelo, A., & Romero, R. (2009). Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants <34 weeks' gestation: A systematic review and meta-analysis. American Journal of Obstetrics and Gynecology, 200(6), 595-609. https://doi.org/10.1016/j.ajog.2009.04.005

Cunningham, J., Rodríguez, M., & Messa, P. (2012). Magnesium in chronic kidney disease stages 3 and 4 and in dialysis patients. Clinical Kidney Journal, 5(Suppl 1), i39-i51. https://doi.org/10.1093/ndtplus/sfr166

Dadelszen, P. von, & Magee, L. A. (2016). Preventing deaths due to the hypertensive disorders of pregnancy. Best Practice & Research. Clinical Obstetrics & Gynaecology, 36(October), 83-102. https://doi.org/10.1016/j.bpobgyn.2016.05.005

DE JESUS, L. C., SOOD, B. G., SHANKARAN, S., KENDRICK, D., DAS, A., BELL, E. F., STOLL, B. J., et al. (2015). Antenatal magnesium sulfate exposure and acute cardiorespiratory events in preterm infants. American Journal of Obstetrics and Gynecology, 212(1), 94.e1-94.e7. https://doi.org/10.1016/j.ajog.2014.07.023

Deeksha, H. S., Pajai, S., & Cherukuri, S. (n.d.). Study based on the alliance between serum magnesium levels and preterm labor: An inclusive review. Cureus, 15(7), e42602. https://doi.org/10.7759/cureus.42602

Doll, E., Wilkes, J., Cook, L. J., Korgenski, K., Faix, R. G., Yoder, B. A., Srivastava, R., et al. (2014). Neonatal magnesium levels correlate with motor outcomes in premature infants: A long-term retrospective cohort study. Frontiers in Pediatrics, 2. Retrieved from https://www.frontiersin.org/articles/10.3389/fped.2014.00120

Eddy, K. E., Vogel, R. I., Zahroh, R. I., & Bohren, M. A. (2022). Factors affecting use of magnesium sulfate for pre‐eclampsia or eclampsia: A qualitative evidence synthesis. Bjog, 129(3), 379-391. https://doi.org/10.1111/1471-0528.16913

Einarson, A., Maltepe, C., Boskovic, R., & Koren, G. (2007). Treatment of nausea and vomiting in pregnancy. Canadian Family Physician, 53(12), 2109–2111.

Euser, A. G., & Cipolla, M. J. (2009). Magnesium sulfate treatment for the prevention of eclampsia: A brief review. Stroke; a Journal of Cerebral Circulation, 40(4), 1169–1175. https://doi.org/10.1161/STROKEAHA.108.527788

Fanni, D., Gerosa, C., Nurchi, V. M., Manchia, M., Saba, L., Coghe, G., Crisponi, G., et al. (2021). The role of magnesium in pregnancy and in fetal programming of adult diseases. Biological Trace Element Research, 199(10), 3647–3657. https://doi.org/10.1007/s12011-020-02513-0

Flenady, V., Wojcieszek, A. M., Papatsonis, D. N., Stock, O. M., Murray, L., Jardine, L. A., Carbonne, B., et al. (2014). Calcium channel blockers for inhibiting preterm labour and birth. The Cochrane Database of Systematic Reviews, 2014(6), CD002255. https://doi.org/10.1002/14651858.CD002255.pub2

Fogel, D. B. (2018). Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. Contemporary Clinical Trials Communications, 11(August), 156–164. https://doi.org/10.1016/j.conctc.2018.08.001

Galinsky, R., Dean, J. M., Lingam, I., Robertson, N. J., Mallard, C., Bennet, L., Gunn, A. J., et al. (2020). A systematic review of magnesium sulfate for perinatal neuroprotection: What have we learnt from the past decade? Frontiers in Neurology, 11. https://www.frontiersin.org/articles/10.3389/fneur.2020.00449

Gordon, R., Magee, L. A., Payne, B., Firoz, T., Sawchuck, D., Tu, D., Vidler, M., Silva, D., & Dadelszen, P. von (2014). Magnesium sulphate for the management of preeclampsia and eclampsia in low and middle-income countries: A systematic review of tested dosing regimens. Journal of Obstetrics and Gynaecology Canada, 36(2), 154–163. https://doi.org/10.1016/S1701-2163(15)30662-9

Gragossian, A., Bashir, K., Bhutta, B. S., Friede, R., et al. (2023). Hypomagnesemia. In StatPearls. Treasure Island (FL): StatPearls Publishing. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK500003/

Jain, S. N., & Mehendale, A. M. (n.d.). A review on umbilical cord milking and its implications in neonatal health. Cureus, 14(10), e30610. https://doi.org/10.7759/cureus.30610

Katageri, G., Charantimath, U., Joshi, A., Vidler, M., Ramadurg, U., Sharma, S., Bannale, S., et al. (2018). Availability and use of magnesium sulphate at health care facilities in two selected districts of North Karnataka, India. Reproductive Health, 15(Suppl 1), 91. https://doi.org/10.1186/s12978-018-0531-6

Kawagoe, Y., Sameshima, H., Ikenoue, T., Yasuhi, I., & Kawarabayashi, T. (2011). Magnesium sulfate as a second-line tocolytic agent for preterm labor: A randomized controlled trial in Kyushu Island. Journal of Pregnancy, 2011, 965060. https://doi.org/10.1155/2011/965060

Khayat, S., Fanaei, H., & Ghanbarzehi, A. (2017). Minerals in pregnancy and lactation: A review article. Journal of Clinical and Diagnostic Research, 11(9), QE01-5. https://doi.org/10.7860/JCDR/2017/28485.10626

Kusyanti, T., Wirakusumah, F. F., Rinawan, F. R., Muhith, A., Purbasari, A., Mawardi, I., Puspitasari, I. W., Faza, A., & Stellata, A. G. (2022). Technology-based (mHealth) and standard/traditional maternal care for pregnant woman: A systematic literature review. Healthcare, 10(7), 1287. https://doi.org/10.3390/healthcare10071287

Lee, C. Y., Chakranon, P., & Lee, S. W. H. (2019). Comparative efficacy and safety of neuroprotective therapies for neonates with hypoxic ischemic encephalopathy: A network meta-analysis. Frontiers in Pharmacology, 10, 1221. https://doi.org/10.3389/fphar.2019.01221

Long, Q., Oladapo, O. T., Leathersich, S., Vogel, J. P., Carroli, G., Lumbiganon, P., Qureshi, Z., & Gülmezoglu, A. M. (2017). Clinical practice patterns on the use of magnesium sulphate for treatment of pre‐eclampsia and eclampsia: A multi‐country survey. Bjog, 124(12), 1883–1890. https://doi.org/10.1111/1471-0528.14400

López Gómez, L., Marín, M. A., Encinas, G. B., de la Cruz Troca, J. J., & Rodríguez Marrodán, B. (2018). Oxytocin receptor antagonist (Atosiban) in the threat of preterm birth: Does it have any effect on breastfeeding in the term newborn? Breastfeeding Medicine, 13(2), 123–128. https://doi.org/10.1089/bfm.2017.0206

Loudon, J. A., Groom, K. M., & Bennett, P. R. (2003). Prostaglandin inhibitors in preterm labour. Best Practice & Research. Clinical Obstetrics & Gynaecology, 17(5), 731–744. https://doi.org/10.1016/s1521-6934(03)00047-6

Lu, J. F., & Nightingale, C. H. (2000). Magnesium sulfate in eclampsia and pre-eclampsia: Pharmacokinetic principles. Clinical Pharmacokinetics, 38(4), 305–314. https://doi.org/10.2165/00003088-200038040-00002

"Magnesium Sulphate Mgso4: Topics by Science.Gov." (n.d.). Retrieved October 31, 2023, from https://www.science.gov/topicpages/m/magnesium+sulphate+mgso4

Matsuda, Y., Maeda, M., Ito, H., Sakamoto, N., Masaoka, M., Takada, M., & Sato, K. (1997). Effect of magnesium sulfate treatment on neonatal bone abnormalities. Gynecologic and Obstetric Investigation, 44(2), 82–88. https://doi.org/10.1159/000291492

Mayer, C., & Apodaca-Ramos, I. (2023). Tocolysis. In StatPearls. Treasure Island (FL): StatPearls Publishing. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK562212/

Miller, E. M. S., Sakowicz, A., Leger, E., Lange, E., & Yee, L. M. (2021). Association between receipt of intrapartum magnesium sulfate and postpartum hemorrhage. AJP Reports, 11(1), e21-25. https://doi.org/10.1055/s-0040-1721671

Modanlou Juibari, H., Eftekharian, H. R., & Arabion, H. R. (2016). Intravenous magnesium sulfate to deliberate hypotension and bleeding after bimaxillary orthognathic surgery; A randomized double-blind controlled trial. Journal of Dentistry, 17(3 Suppl), 276-282.

Moradi, Y., Khateri, R., Haghighi, L., Dehghani, S., Mansouri, H., Mehrdad, V., Valipour, Z., Najmi, Z., Fathollahy, M., Allahmoradi, K., & Mansori, K. (2020). The effect of antenatal magnesium sulfate on intraventricular hemorrhage in premature infants: A systematic review and meta-analysis. Obstetrics & Gynecology Science, 63(4), 395-406. https://doi.org/10.5468/ogs.19210

"Muscle Weakness: 12 Causes and More." (2019, July 26). Retrieved from https://www.medicalnewstoday.com/articles/325876

Olofsson, P., Forsberg, K., Marsál, K., & Sjöberg, N. O. (1992). Short-term effect of magnesium sulfate infusion on renal function in preeclamptic women. Journal of Perinatal Medicine, 20(5), 361-364. https://doi.org/10.1515/jpme.1992.20.5.361

Padda, J., Khalid, K., Colaco, L., Padda, S., Boddeti, N. L., Khan, A. S., Cooper, C., & Jean-Charles, G. (n.d.). Efficacy of magnesium sulfate on maternal mortality in eclampsia. Cureus, 13(8), e17322. https://doi.org/10.7759/cureus.17322

Petla, L. T., Chikkala, R., Ratnakar, K. S., Kodati, V., & Sritharan, V. (2013). Biomarkers for the management of pre-eclampsia in pregnant women. The Indian Journal of Medical Research, 138(1), 60-67.

Popkin, B. M., D'Anci, K. E., & Rosenberg, I. H. (2010). Water, hydration and health. Nutrition Reviews, 68(8), 439-458. https://doi.org/10.1111/j.1753-4887.2010.00304.x

PubChem. (n.d.). Magnesium sulfate. Retrieved October 31, 2023, from https://pubchem.ncbi.nlm.nih.gov/compound/24083

Rouse, D. J., Hirtz, D., Thom, E., Varner, M. W., Spong, C. Y., Mercer, B. M., Iams, J. D., et al. (2008). A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. The New England Journal of Medicine, 359(9), 895-905. https://doi.org/10.1056/NEJMoa0801187

Satyanarayana Rao, K. H. (2008). Informed consent: An ethical obligation or legal compulsion? Journal of Cutaneous and Aesthetic Surgery, 1(1), 33-35. https://doi.org/10.4103/0974-2077.41159

Sebastiani, G., Navarro-Tapia, E., Almeida-Toledano, L., Serra-Delgado, A., Paltrinieri, L., García-Algar, Ó., & Andreu-Fernández, V. (2022). Effects of antioxidant intake on fetal development and maternal/neonatal health during pregnancy. Antioxidants, 11(4), 648. https://doi.org/10.3390/antiox11040648

"Severe Pre-Eclampsia/Eclampsia Management (Green-Top Guideline No. 10A)." (n.d.). RCOG. Retrieved October 31, 2023, from https://www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/severe-pre-eclampsiaeclampsia-management-green-top-guideline-no-10a/

Shennan, A., Suff, N., Jacobsson, B., Simpson, J. L., Norman, J., Grobman, W. A., Bianchi, A., Mujanja, S., Valencia, C. M., & Mol, B. W. (2021). FIGO Good Practice Recommendations on Magnesium Sulfate Administration for Preterm Fetal Neuroprotection. International Journal of Gynaecology and Obstetrics, 155(1), 31-33. https://doi.org/10.1002/ijgo.13856

Simon, J., Gray, A., Duley, L., & Magpie Trial Collaborative Group. (2006). Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: Economic evaluation of the Magpie trial. BJOG: An International Journal of Obstetrics and Gynaecology, 113(2), 144-151. https://doi.org/10.1111/j.1471-0528.2005.00785.x

Stevenson, D. K., Wong, R. J., Aghaeepour, N., Maric, I., Angst, M. S., Contrepois, K., Darmstadt, G. L., et al. (2021). Towards personalized medicine in maternal and child health: Integrating biologic and social determinants. Pediatric Research, 89(2), 252-258. https://doi.org/10.1038/s41390-020-0981-8

Tang, J., He, A., Li, N., Chen, X., Zhou, X., Fan, X., Liu, Y., et al. (2018). Magnesium sulfate-mediated vascular relaxation and calcium channel activity in placental vessels different from nonplacental vessels. Journal of the American Heart Association, 7(14), e009896. https://doi.org/10.1161/JAHA.118.009896

Wedig, K. E., Kogan, J., Schorry, E. K., & Whitsett, J. A. (2006). Skeletal demineralization and fractures caused by fetal magnesium toxicity. Journal of Perinatology: Official Journal of the California Perinatal Association, 26(6), 371-374. https://doi.org/10.1038/sj.jp.7211508

WHO Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia. (n.d.). Retrieved October 31, 2023, from https://www.who.int/publications-detail-redirect/9789241548335

Wilson, A., Hodgetts-Morton, V., Marson, E. J., Markland, A. D., Larkai, E., Papadopoulou, A., Coomarasamy, A., et al. (2022). Tocolytics for delaying preterm birth: A network meta-analysis. The Cochrane Database of Systematic Reviews, 8(8), CD014978. https://doi.org/10.1002/14651858.CD014978.pub2

Younger, J. D., Reitman, E., & Gallos, G. (2017). Tocolysis: Present and future treatment options. Seminars in Perinatology, 41(8), 493-504. https://doi.org/10.1053/j.semperi.2017.08.008

Zarean, E., & Tarjan, A. (2017). Effect of magnesium supplement on pregnancy outcomes: A randomized control trial. Advanced Biomedical Research, 6(August), 109. https://doi.org/10.4103/2277-9175.213879

Zeng, X., Xue, Y., Tian, Q., Sun, R., & An, R. (2016). Effects and safety of magnesium sulfate on neuroprotection. Medicine, 95(1), e2451. https://doi.org/10.1097/MD.0000000000002451